Back
Apellis Pharmaceuticals, Inc. Stock Predictions
Missed $0.81? RAD Intel Now Open at $0.85/Share
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
47
APLS
Apellis Pharmaceuticals, Inc.
Last Price:
$22.20
Seasonality Move:
12.69%
7 Day Trial
ALL ACCESS PASS
$
7
This AI Layer Just Raised Its Share Price
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiApellis Pharmaceuticals, Inc. Stock Forecast
-
Over the next 52 weeks, Apellis Pharmaceuticals, Inc. has on average historically risen by 12.3% based on the past 8 years of stock performance.
-
Apellis Pharmaceuticals, Inc. has risen higher in 5 of those 8 years over the subsequent 52-week period, corresponding to a historical accuracy of 62.5%
-
Is Apellis Pharmaceuticals, Inc. Stock Undervalued?The current Apellis Pharmaceuticals, Inc. [APLS] share price is $22.19. The Score for APLS is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.
-
APLS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
Will Apellis Pharmaceuticals, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Apellis Pharmaceuticals, Inc. has on average historically risen by 12.3% based on the past 8 years of stock performance.
Apellis Pharmaceuticals, Inc. Stock Rating
Sell
47
Apellis Pharmaceuticals, Inc. (APLS)
is a Sell
Is Apellis Pharmaceuticals, Inc. overpriced?
-
Apellis Pharmaceuticals, Inc. has risen higher in 5 of those 8 years over the subsequent 52-week period, corresponding to a historical accuracy of 62.5%
Apellis Pharmaceuticals, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
apellis.com
52-Week Data
52-Week High:
35.72
52-Week Low:
16.10
Prediction Charts
Market Cap:
2.8B
Price in USD:
22.19
Volume:
2.6M
Beta:
0.88
Technical Analysis
SMA50:
22.91
SMA100:
23.61
SMA200:
22.01
52-Wk Change:
-34.98%
Stock Predictions
-
Is Apellis Pharmaceuticals, Inc. stock public?Yes, Apellis Pharmaceuticals, Inc. is a publicly traded company.
-
What is the Apellis Pharmaceuticals, Inc. stock quote today?The Apellis Pharmaceuticals, Inc. stock price is 22.19 USD today.
-
How to buy Apellis Pharmaceuticals, Inc. stock online?You can buy Apellis Pharmaceuticals, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-14 | 19.65 | 20.33 | 20.70 | 19.65 |
| Nov-17 | 20.06 | 20.10 | 20.58 | 19.99 |
| Nov-18 | 19.81 | 19.73 | 20.21 | 19.68 |
| Nov-19 | 19.61 | 19.45 | 19.83 | 19.31 |
| Nov-20 | 19.68 | 19.54 | 19.91 | 19.48 |
| Nov-21 | 19.45 | 19.61 | 19.95 | 19.40 |
| Nov-24 | 19.62 | 20.13 | 20.36 | 19.50 |
| Nov-25 | 20.05 | 21.00 | 21.14 | 19.99 |
| Nov-26 | 21.08 | 21.59 | 21.71 | 20.90 |
| Nov-28 | 21.61 | 21.30 | 21.72 | 21.11 |
| Dec-1 | 21.05 | 21.20 | 21.38 | 21.00 |
| Dec-2 | 21.20 | 20.66 | 21.34 | 20.51 |
| Dec-3 | 20.80 | 21.25 | 21.32 | 20.61 |
| Dec-4 | 21.21 | 22.19 | 22.45 | 21.16 |
Apellis Pharmaceuticals, Inc. Earnings
Apellis Pharmaceuticals, Inc. Earnings Report: Per Share Apellis Pharmaceuticals, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Apellis Pharmaceuticals, Inc. Forecast Revenue Growth
Apellis Pharmaceuticals, Inc. Stock Analysis: Historical quarterly revenues per share for Apellis Pharmaceuticals, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $1.24 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.00 per share, and a decrease next year of $1.42 per share.
* Apellis Pharmaceuticals, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.